Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.
Site search
2025
May 23, 2025
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT Trial of Zipalertinib at ASCO 2025
May 23, 2025
Results of Clinical Study of the Combination Regimen of
March 17, 2025
Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech（PDF：236.3 KB）
February 26, 2025
Solar Power Generation Facility Launched at Taiho Pharmaceutical's Kitajima Plant to Accelerate Carbon Neutrality Initiatives（PDF：375.5 KB）
February 07, 2025
Otsuka Group Selected for CDP Climate Change A List for a Third Consecutive Year
January 29, 2025
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy（PDF：180.4 KB）
News Releases
Select year from the Back Number
Back Number
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
